Aadi Starts Small With Fyarro, But Has Tumor-Agnostic Strategy In Mind
Executive Summary
The approval of Fyarro marks the first for advanced malignant PEComa, a rare cancer that affects only 100-300 people in the US; it's also the first launch for Aadi Biosciences.
You may also be interested in...
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves
The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. Other CDK2 inhibitors have had ocular toxicity issues as well.
Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals
Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.